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Objective: A dire shortage of lungs for transplantation exists. We hypothesized that
aggressive organ procurement organization management of lungs usually rated as
unacceptable (ratio of PaO2 to inspired oxygen fraction 150) might make them
acceptable for transplantation. We also hypothesized that lungs from donors who
died of trauma could be used for transplantation with recipient survival comparable
with that seen with lungs from donors who died of nontraumatic causes.
Methods: From January, 1, 1995, through August 31, 2000, a total of 194 donors
resulted in 228 lung transplants. Of these, 27 donors were deemed unacceptable for
lung transplantation according to organ procurement organization protocol. We used
the California Transplant Donor Network database to conduct a retrospective review
of all 194 donors, including the 27 supposedly unacceptable donors who were treated
with invasive monitoring (central venous pressure), methylprednisolone, fluid restric-
tion, inotropic agents, bronchoscopy, and diuresis. We evaluated survivals at 30 days
and 1 year of patients who received lungs rated as unacceptable and acceptable. In
addition, we compiled data on recipient survival for a subgroup of 122 recipients with
lungs from donors who died of trauma and compared these data with those of
recipients who received lungs from donors who died of nontraumatic causes to see
whether the donor’s death by trauma resulted in higher recipient mortality.
Results: After aggressive organ procurement organization management, ratios of PaO2
to inspired oxygen fraction, central venous pressures, fluid balances, dopamine require-
ments, and chest radiographs of unacceptable donors according to organ procurement
organization criteria were comparable with those of acceptable donors. There were no
significant differences in recipient mortality between groups at 30 days or 1 year after
transplantation. Moreover, no significant difference was found in mortalities of recipi-
ents who received lungs from donors who died of traumatic and nontraumatic causes.
Conclusion: Aggressive organ procurement organization management of donors initially
considered unacceptable may increase the number of lungs available for transplantation.
The incidence of end-stage lung disease has grown in the UnitedStates during the last 20 years,1 and lung transplantation is now anaccepted treatment option for many of these patients. Last year, eventhough 877 lung transplants were performed in the United States,more than 2100 patients were added to the lung transplant waitinglist. Almost 3500 patients are currently awaiting lung transplanta-
tion, and it is estimated that 600 of them will die before an organ becomes
available.2 A shortage of donor lungs remains the critical limiting factor.
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It is known that more than 80% of multiorgan donors do
not have at least one lung used. Data released by the
Association of Organ Procurement Organizations (AOPO)
for the year 2000 reveal that among the nation’s 25 largest
organ procurement organizations (OPOs) the average lung
procurement was only 13.4%. The variability of percentages
among OPOs was even more striking (6.1%-27.1%).3 Rea-
sons for this wide discrepancy are multifaceted and include
wide variations in donor management protocols, proximity
of local lung transplantation centers, and OPO experience in
maintaining lung donors.4,5
Traditionally, strict inclusion criteria for lung transplant
donors have been required of OPOs by the transplantation
centers. One approach to overcome this limitation has been
liberalization of donor selection criteria to expand the avail-
able donor pool.6-8 Ideal lung donor selection criteria are
age younger than 55 years; ABO compatibility, clear chest
radiograph, PaO2 greater than 300 mm Hg with an inspired
oxygen fraction (FIO2) of 1.0 and positive end-expiratory
pressure of 5 cm H2O (PaO2/FIO2 ratio 300), tobacco use
history equivalent to less than 20 pack-years; absence of
chest trauma, absence of aspiration or sepsis, lack of previ-
ous cardiopulmonary surgery, absence of organisms on spu-
tum Gram stain, and absence of purulent secretions at bron-
choscopy.9-11 Bhorade and colleagues6 studied donors who
did not meet just one of these criteria, referring to them as
“extended donors.” They found that when these extended
donors were used, the 1-year posttransplantation outcome
was not adversely effected provided that oxygenation was
maintained before lung procurement (PaO2/FIO2 ratio main-
tained 300).
Other strategies to increase the number of donor lungs
include attempts to improve the condition of donors con-
sidered unacceptable (those missing one or more of the ideal
criteria and with PaO2/FIO2 ratios less than 150) by medical
management. Traditionally in our OPO, lung donors with
PaO2/FIO2 ratios less than 150 have been unquestioningly
rejected, without consideration of the reversibility of the
pulmonary insult. Several OPO centers have adopted ag-
gressive management strategies to convert these initially
unacceptable donors into acceptable ones.12,13 Little is
known, however, about the long-term outcomes of the re-
cipients of these previously unacceptable lungs that have
been made acceptable by aggressive OPO management.
One purpose of this review was to determine the outcomes
when these donors were used.
How a donor dies may also play a role in recipient
outcome. Traumatic wet lung was first described in 1945
and is recognized as a cause of respiratory dysfunction in
patients with trauma.14 It has been hypothesized that trauma
as a cause of death results in a greater number of early and
late posttransplantation complications, although this hy-
pothesis has never been carefully studied or validated.
In our retrospective study we evaluated the hypothesis
that donor lungs with unacceptable PaO2/FIO2 ratios (150)
can be made acceptable with aggressive OPO management
and that 30-day and 1-year recipient outcomes with these
lungs would not be significantly different than the outcomes
of recipients with traditionally ideal lungs. We also com-
pared the 30-day and 1-year outcomes of recipients with
lungs from donors with traumatic and nontraumatic causes
of death. We analyzed two groups of donors: acceptable
donors, which included ideal donors and all donors who had
one or more extended criteria but maintained PaO2/FIO2
ratios greater than 300 at the time of procurement, and
unacceptable donors, those with a PaO2/FIO2 ratio less than
150. We also compared the early and late results of recip-
ients of lungs from donors with traumatic and nontraumatic
causes of death.
Methods
From January 1, 1995, through August 31, 2000, a total of 194
donors resulted in 228 lung transplants. The lung donor group
came from a potential pool of 1037 donors identified during the
study. A retrospective analysis of the computerized database of the
California Transplant Donor Network was used to review data for
this study. Initial evaluation of all donors included age, smoking
history, use of inhaled drugs, chest radiographic evaluation, mea-
surement of PaO2/FIO2 ratio, and sputum Gram stains. Unaccept-
able donors were discriminated by initial poor oxygenation (PaO2/
FIO2 150). Acceptable donors were those who met ideal criteria
when OPO management began and maintained these criteria until
procurement and those who had one or more criteria that classified
them as expanded donors (Table 1) but at procurement had a
normal chest radiograph and a PaO2/FIO2 ratio greater than 300. We
compared the 30-day and 1-year survivals of recipients receiving
lungs from unacceptable donors with those of recipients receiving
lungs from acceptable donors. To determine whether death from
trauma had an adverse effect on 30-day and 1-year lung recipient
survivals, survivals of recipients of lungs from donors with trau-
matic causes of death were compared with those of recipients of
lungs from donors with nontraumatic causes of death.
Aggressive management of all 27 unacceptable donors con-
sisted of invasive central venous pressure (CVP) monitoring,
methylprednisolone (15 g/kg) immediately after declaration of
brain death, fluid restriction, inotropes (dopamine drops) titrated
for hemodynamic stability, bronchoscopy, diuresis, and radio-
graphic review. The number of donors with a PaO2/FIO2 less than
150 who did not donate at least one lung was not available from
our database. The decision to give steroids was based in part on
transplantation center preferences. Type of transplantation per-
formed (single-lung, double-lung, or heart-lung transplant) was
recorded for all groups. Survival of recipients with lungs from the
27 unacceptable donors at 30 days and 365 days were compared
with those of recipients of lungs from the 38 ideal donors and the
entire group of 166 acceptable (expanded plus ideal) donors.
Median survival was then calculated with 95% confidence inter-
vals for each of the three groups. Information and transplantation
follow-up were provided by the California Transplant Donor Net-
work with a standard AOPO form. Data on hospital length of stay
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after transplantation were also compared between groups. In ad-
dition, to see whether the recipient diagnosis affected survival
differently according to the donor group, a Cox proportional haz-
ard model was used. The two groups were compared with respect
to selected variables—age, sex, cause of death, race, donor ABO
type, and use of steroids immediately before procurement—to
determine whether demographic, historical, or management factors
were associated with increased likelihood of successful transplan-
tation. Additional data for the unacceptable group included lowest
PaO2/FIO2 ratio, final PaO2/FIO2 ratio, CVP when OPO manage-
ment began, final CVP, fluid balance from donor arrival to inter-
vention by OPO, fluid balance from OPO intervention to procure-
ment, and dopamine dosages when OPO management began and at
procurement.
Statistical analysis was performed with SPSS computer soft-
ware (SPSS Inc, Chicago, Ill). Measurements are reported as
mean  SEM. A 2-tailed Student t test was applied to all numeric
data. Categoric data were analyzed by 2 analysis. Survival data
were calculated by Kaplan-Meier analysis. A Cox proportional
hazard model was used to discriminate variables within the study
groups.
Results
Comparisons of unacceptable, ideal, and acceptable donors
revealed that the unacceptable donors were predominantly
male (P  .034) and the cause of death was predominantly
trauma (P  .005; Table 2). There were no statistically
significant differences in ethnicity, age, or ABO blood type
among unacceptable and acceptable groups. All unaccept-
able donors received methylprednisolone after declaration
of brain death, whereas only 78% of the acceptable donors
received steroids (P  .0036; Table 2). The ideal donors
(Table 3) did not differ from the unacceptable donors with
respect to gender or ethnicity, but significantly fewer of the
ideal donors than the unacceptable donors received steroids
(P  .002). Dopamine was titrated to minimal doses to
maintain organ perfusion (Table 4), and dopamine require-
ments had decreased significantly by the time of procure-
ment (P  .005). In the unacceptable donor group, PaO2/
FIO2 ratios before OPO management were low; after
management, they rose significantly (P .005). Initial CVP
measurements were high before OPO intervention; from the
TABLE 1. Criteria for ideal and expanded lung donor groups
Ideal criteria
(n  38 donors)
Extended criteria (n  129 donors)
Criterion
Donors meeting
criterion (%)
PaO2/FIO2 ratio 300 300 24.8
Age (y) 55 55 7.8
Smoking (pack-year) 20 20 2.3
Chest radiograph Clear Abnormal 26.4
Bronchoscopy Clean Presence of organisms
(cleared after
management)
6.2
Inhaled drugs No Yes 10
More than 1 extended criterion Not applicable Yes 22.4
*Ideal donors met all the ideal criteria during the entire management period. Donors in the expanded group met one or more of the extended criteria (as
defined by Bhorade and colleagues6) during OPO management but maintained a PaO2/FIO2 ratio greater than 300 and had a normal chest radiograph at time
of organ procurement.
TABLE 2. Donor variables
Donor parameter
Unacceptable
donor group
(n  27)
Acceptable
donor group
(n  167)
P
value
Age (y, mean  SEM) 26.4 2 31.2 1 .13
Gender (no.)
Male 21 (77.8%) 92 (54.8%) .034
Female 6 (22.2%) 75 (45.2%)
Donor ethnicity (no.) .94
White 17 (63%) 109 (65.1%)
Other 10 (37%) 58 (34.9%)
Cause of death (no.) .005
Trauma 20 (74.1%) 79 (47.6%)
Nontraumatic 7 (25.9%) 88 (52.4%)
Steroid use (no.) 27 (100%) 130 (78%) .0036
TABLE 3. Unacceptable versus ideal donor variables
Donor parameter
Unacceptable
donor group
(n  27)
Ideal
donor group
(n  38)
P
value
Age (y, mean  SEM) 26.4 2 28.7 1.9 .47
Gender (no.)
Male 21 (77.8%) 22 (57.9%) .095
Female 6 (22.2%) 16 (42.1%)
Donor ethnicity (no.) .93
White 17 (63%) 21 (55.3%)
Other 10 (37%) 17 (44.7%)
Cause of death (no.) .121
Traumatic 20 (74.1%) 2 (55.3%)
Nontraumatic 7 (25.9%) 17 (44.7%)
Steroid use (no.) 27 (100%) 27 (71.1%) .002
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time of OPO management to the time of organ procurement,
CVP measurements dropped significantly (P  .05). Fluid
balance before OPO management was positive (4L); after
management, it became negative (P  .008). Chest radio-
graphs were interpreted by an attending radiologist as hav-
ing abnormal findings initially for most unacceptable do-
nors; all radiographs showed subsequent correction to a
normal appearance at the time of procurement (P  .051).
There were also no differences in 30-day and 1-year sur-
vivals between donors who received low doses ( 20 g/
[kg  min]) or high doses ( 20 g/[kg  min]) of dopamine
during management (Table 5). Hospital stay averaged
16.06  1.4 days in the unacceptable donor group. This
compared favorably with 16.5  1.9 in the ideal group and
20 1.9 in the extended group. The data for hospital length
of stay were not statistically significantly different among
groups.
Recipient survivals at 30 days and 1 year were not
different among the donor groups (Tables 5, 6, and 7 and
Figure 1). The median survivals for all recipients were not
different among groups (P .70 by log-rank test; Figure 1).
We believe that the reason for the slight drop in the ideal
donor group survival at 1 year (79.1%) was that all heart-
lung transplants came from this group (Table 6). It is
important to note that all donors from all groups went to the
operating room with a normal chest radiograph and a PaO2/
FIO2 ratio greater than 300. The numbers of extended criteria
that were met by each of our expanded donors at the time of
OPO management are listed in Table 1. Twenty-two percent
of these donors had more than one extended criterion, with
PaO2/FIO2 ratio and an abnormal radiograph being the most
common combination (13.9%).
The recipients of organs from donors with traumatic
causes of death had the same 30-day and 1-year survivals as
did the recipients of lungs from donors who died of non-
traumatic causes (Table 7; Figure 2). There were statisti-
cally more male donors with trauma as the cause of death,
and the average age was lower among the donors with
trauma as the cause of death than among the ideal and
acceptable donor groups.
Recipient diagnosis (Tables 8 and 9) did not affect sur-
vival according to the donor lung group. The 95% confi-
dence interval for the Cox proportional hazard model indi-
cated no statistical relationship between donor group and
recipient survival controlling for recipient diagnosis.
Discussion
Aggressive OPO management of unacceptable donors re-
sulted in improved oxygenation, hemodynamics, and chest
radiographs at the time of lung procurement. The resultant
organs were successfully transplanted without compromise
of either 30-day or 1-year graft survival relative to lungs
from both the ideal group and the acceptable group of
donors. Expanded group donors had one or more criteria
that would not have been traditionally approved; our accept-
able group included ideal and expanded donors. At the time
of procurement all donors had normal chest radiographs and
a PaO2/FIO2 ratio greater than 300. The ability to reverse the
effects of aggressive fluid resuscitation, early pulmonary
edema, and inflammation allowed these organs to be trans-
planted without adverse short- or long-term effects on the
recipients.
The limitations of our study include the retrospective
design, the small sample size, and the fact that all trans-
plants were not performed at the same institution. The data
were collected by a single OPO that serves a large geo-
graphic area with a number of transplantation centers. At the
time of this study, standardized protocols had not been
implemented between transplantation centers with respect
to preoperative, intraoperative, and postoperative manage-
ment. In addition, data on recipient selection, causes of
death, and complications were not available from the trans-
plantation centers. Recipient selection could certainly skew
the data, but these limitations were beyond the control of
our OPO. We are currently gathering data regarding recip-
ient posttransplantation pulmonary function, incidence of
obliterative bronchiolitis, and causes of death, but the data
are only available for those recipients who have undergone
transplantation within the last 6 month and are therefore not
reported.
In the United States the most frequently reported indica-
tions for lung transplantation are emphysema or chronic
obstructive pulmonary disease, cystic fibrosis, and pulmo-
TABLE 4. Results of management of the unacceptable do-
nor group
Variable (n  27 donors)
Before OPO
management
At organ
procurement
P
value
PaO2/FIO2 (mean  SEM)* 103 6 463 11 .001
FIO2 (mean  SEM)* 86% 5% 100%
CVP (mm Hg, mean  SEM) 11.3 0.9 6.7 0.4 .05
Net fluid balance (L, mean 
SEM)
4.1 1.3 1.7 0.8 .008
Dopamine requirement (g/
[kg  min], mean  SEM)
15 0.1 5.2 0.6 .001
Abnormal chest radiograph
(no.)
20/26 0/26 .05
*Positive end-expiratory pressure of 5 mm Hg.
TABLE 5. Recipient survivals at 30 days and 1 year related
to dopamine dosage in unacceptable donor group
Dopamine dose
High dose
(>20 g/ [kg  min])
Low dose
(<20 g/[kg  min])
P
value
Survival at 30 d 83.3% 95.5% .279
Survival at 1 y 83.3% 90.9% .602
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nary fibrosis.15 The shortage of donor organs has been the
critical limiting factor in the treatment of end-stage lung
disease. Although there has been an increase in the number
of patients on the transplant waiting list, there has not been
a corresponding increase in the number of available donor
lungs.16-18 Furthermore, the AOPO documented an abys-
mally low rate of lung procurement from available donors,
averaging only 13.4% among the 25 largest OPOs in 2000.
Of more concern was the wide variability among OPOs with
respect to lung procurement rates, suggesting that donor
management may have dramatic effects on procurement
success. Although the use of unsuitable organs would be
catastrophic, many investigators are challenging the severe
limitations imposed on lung transplant donor selection by
what some consider arbitrary and rigid lung donation stan-
dards.6-8
Traditional lung transplant donor selection criteria for
ideal candidates are listed in Table 1. Bhorade and col-
leagues6 demonstrated that extending their donor criteria to
include what they called “marginal” donors did not ad-
versely affect either short- or long-term recipient survival
outcomes. They defined marginal donors as having any one
of the following criteria: age older than 55 years, tobacco
history of more than 20 pack-years, presence of infiltrate on
chest radiograph, ventilator time longer than 5 days, or
donor use of inhaled drugs (cocaine or marijuana). Interest-
ingly, oxygenation was one criterion on which these inves-
tigators did not compromise. Each of the marginal donors
maintained PaO2/FIO2 ratios greater than 350 at procure-
ment. Bhorade and colleagues6 found no significant differ-
TABLE 6. Recipient survivals* with unacceptable, extended, and ideal donor lungs
Type of transplant
Recipients of lungs from
unacceptable donor group
Recipients of lungs from
extended donor group
Recipients of lungs from
ideal donor group P value†
All recipients .70
Median 2202 1575 1810
95% Confidence interval 706-2202 1224-2172 1046-2187
Lung transplants .59
Median 2202 1368 2073
95% Confidence interval 706-2202 1093-1893 721-2073
Heart-lung transplants .58
Median ‡ 2172 1810
95% Confidence interval ‡ 736-2281 334-2187
*Survival by Kaplan-Meier analysis.
†By log-rank test.
‡Unacceptable donor group was not considered for heart-lung transplants.
TABLE 7. Survivals* of recipients by donor cause of death
Survival time (d)
Traumatic
cerebral deaths
(n  122)
Nontraumatic
cerebral deaths
(n  106)
P
value†
Median 1812 1575 .86
95% Confidence interval 1334-2172 981-2281
*Survival in days by Kaplan-Meier analysis.
†By log-rank test.
Figure 1. Kaplan-Meier survival curves comparing recipients of
lungs from unacceptable, acceptable, and ideal donors. Note that
there were no significant survival differences by donor group.
Figure 2. Kaplan-Meier survival curves comparing recipients of
lungs from donors who died of trauma and those who died of
nontraumatic causes. Note that there were no significant survival
difference by donor group.
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ence in 30-day and 1-year outcomes between the recipients
of lungs from expanded donors (marginal lungs) and recip-
ients of lungs from ideal donors. At 1 year after transplan-
tation, the investigators noted a trend toward decreased
pulmonary function in patients who received a single mar-
ginal donor lung, although this trend did not attain statistical
significance. They therefore concluded that certain ex-
panded criteria did not preclude successful transplantation,
which would argue for a potential increase in the number of
available donors.6
Sundaresan and associates7 also reviewed their experi-
ence with marginal donors. Their marginal group included
37 donors who failed to meet one traditional ideal donor
criteria and 7 donors who failed to meet two criteria. Six
donors in their marginal group had preoperative PaO2/FIO2
ratios less than 300, although their actual values were not
defined. They made no aggressive attempts before procure-
ment to improve the oxygenation of these donor lungs. They
noted no difference in early oxygenation, length of ventila-
tor support, and 30-day survivals when they compared re-
cipients who received marginal lungs with those who re-
ceived ideal lungs. Long-term follow-up was not available
in their study, however, which leads to speculation about
delayed pulmonary function and survival of these recipi-
ents.
Transplantation of lungs from donors involved in major
trauma has traditionally been avoided because pulmonary
dysfunction (often delayed in presentation) is a common
sequela of major trauma. In addition to the initial pulmonary
injury (contusion, laceration, and aspiration), circulating
platelet and protein microaggregates are taken up by the
pulmonary microcirculation, which can lead to endothelial
injury by neutrophil activation.19,20 Aggressive intravenous
fluid administration during the initial resuscitation only
compounds the alveolar injury and may cause pulmonary
edema. Waller and coworkers21 demonstrated that donor
death by trauma did not affect the following indices of graft
function at 30 days: length of postoperative ventilation,
PaO2/FIO2 ratios at 1 hour and 24 hours, incidence of diffuse
alveolar damage in lung biopsy specimens at 7 days, and
30-day mortality. However, 30% of their early recipient
mortality was directly related to the clinical condition of the
donor at the time of transplantation. Specifically, death from
gram-negative bacterial pneumonia, in which the causative
organisms were present at donor bronchoalveolar lavage,
could potentially have been prevented. They concluded that
using donor lungs from patients who die of trauma does not
in itself compromise early graft outcome, provided that
appropriate management strategies are used, including an-
tibiotic treatment on the basis of bronchoscopy cultures
after transplantation. Our study corroborates this and dem-
onstrates no difference in 30-day and 1-year survivals of
TABLE 9. Recipient survival relationship to donor group
Relative hazard
95% Confidence
interval P value
Unacceptable donors 0.64 0.29-1.41 .27
Extended donors 0.93 0.54-1.62 .80
Cox proportional hazard regression analysis for recipient diagnosis (as
listed in Table 8). Reference group was ideal donor group.
TABLE 8. Pretransplantation diagnoses among lung transplant recipients
Diagnosis
Recipients of lungs from
unacceptable donor group
Recipients of lungs from
ideal donor group
Recipients of lungs from
acceptable donor group
Chronic obstructive pulmonary disease and emphysema
(includes 1-antitrypsin deficiency)
No. 15 12 57
% 44.2 27.9 37.8
Cystic fibrosis
No. 7 7 20
% 20.6 16.3 13.2
Pulmonary hypertension (includes Eisenmenger disease)
No. 4 15 46
% 11.8 34.9 30.4
Pulmonary fibrosis
No. 8 8 25
% 23.5 18.6 30.4
Retransplantation
No. 0 1 3
% 0 2.3 2.0
Total recipients
No. 34 43 151
% 100 100 100
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lung grafts between those from donors who died of trauma
and those who died of nontraumatic causes. In addition, we
found that a greater number of our unacceptable donors
were those who died of trauma, suggesting that the early
lung dysfunction associated with trauma may be completely
reversible.
Irrespective of the cause of death, most donors display
some lung dysfunction before procurement. Kron and asso-
ciates8 recently hypothesized that mild pulmonary dysfunc-
tion was common among potential lung donors and should
be treated after lung transplantation. They performed a
prospective study that required personal evaluation by the
transplant surgeons of all potential thoracic organ donors.
All donors met certain criteria: PaO2/FIO2 ratio less than 350
but more than 300, presence of infiltrate on radiograph, or
purulent secretions at bronchoscopy. Kron and associates8
accepted lungs from donors who had been receiving me-
chanical ventilation for less than 48 hours whose secretions
could be cleared with suction and whose Gram stain did not
reveal fungus. Antibiotic regimens were tailored to the
organisms found on Gram stain from bronchoscopy speci-
mens and strictly adhered to after culture results. They
confirmed that minor infiltrates from atelectasis and secre-
tions could be treated after transplantation and that minor
abnormalities in gas exchange could be corrected after
transplantation by appropriate fluid and ventilator manage-
ment. Long-term follow-up, however, was not available in
their study.
Successful lung procurement can be optimized with ag-
gressive donor management. The most common reasons for
loss of donor lungs for transplantation are pulmonary
edema, pulmonary sepsis, and contusions.22 Cummins and
colleagues13 recently evaluated their donor management
strategies. Their protocols focused on maximized ventila-
tory support, judicious fluid management, and maintenance
of aggressive pulmonary toilet. Crystalloid rather than col-
loid fluids were administered, with targets of urinary output
greater than 100 mL/h, systolic blood pressures greater than
100 mm Hg, and CVPs of 6 to 8 mm Hg. Vasopressors were
used as needed to maintain organ perfusion. The goals of
ventilator therapy were to maintain adequate oxygen satu-
ration with minimal FIO2, to provide adequate ventilation to
maintain normal acid-base balance, and to prevent inade-
quate ventilation and atelectasis. Chest physiotherapy was
performed hourly, including sterile saline solution lavage
and hyperventilation. Sputum Gram stains were obtained
early, and antibiotic treatment was tailored to those results.
A dramatic increase in lung procurement was demonstrated
when these guidelines were followed. The retrieval rate of
33% reported by Cummins and colleagues13 was better than
that of the largest centers reported by the AOPO.3
The 27 unacceptable donors would have been rejected by
OPO protocol as lung donors at their initial evaluation
because of their poor oxygenation. We do not know how
many potential donors during the study period had a PaO2/
FIO2 ratio less than 150 that could not be optimized, and this
presents a limitation of this study. However, we have shown
that the aggressive use of CVP monitoring, diuresis, ste-
roids, and vasopressors allowed each of our 27 donors in the
unacceptable group to have their lungs successfully trans-
planted. No untoward effects could be attributed to this
effort, and the number of recipients surviving was compa-
rable with the survival of all other recipients, including
those who received ideal organs. We also demonstrated that
the recipient diagnosis and whether the recipient received an
organ from this unacceptable group did not adversely affect
the recipient outcome. At a time when donor organs are so
precious, every effort must be made to optimize donor
selection. Our study shows that special attention needs to be
placed on donor management, especially for donors who die
of trauma, because many of the initial insults are reversible
with aggressive intervention. Early and long-term survivals
of recipients of lungs from persons who died of trauma were
not significantly different from those who died of nontrau-
matic causes. We do not know at present whether donor
trauma will affect the late results of lung transplant recipi-
ents at 5 years after transplantation. We will be following up
these patients carefully to try and answer this question.
We believe that one way to increase the number of
acceptable lungs for transplantation is by the widespread
use of aggressive management protocols by all OPOs. The
wide variability seen among OPOs in terms of lung pro-
curement rates may be lessened if standard management
criteria are adopted and used. We also believe that all OPOs
should define their pool of potential lung donors to exclude
older and younger patients who would never be considered
candidates for lung donation, thus ensuring a more accurate
means of comparing OPO performance. It is our belief that
if lung retrieval rates could be increased to a constant level
nationally, consistent with the level in the most successful
OPOs, there would be a large increase in the number of
lungs available for transplantation.
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Discussion
Dr Robert C. Robbins (Stanford, Calif). This study was designed
to test the hypothesis that donors with unacceptable PaO2/FIO2
ratios of less than 150 could become acceptable lung donors with
aggressive OPO management and that the 30-day and 1-year
outcomes would be no different from the results achieved with
traditional ideal donors. Straznicka and coworkers also investi-
gated the results of pulmonary transplants from donors who had
sustained traumatic injuries and compared them with the results of
transplants from donors without a history of traumatic injury.
This article addresses an important area of investigation, be-
cause there is a severe imbalance in the supply of donor lungs for
the demand of patients awaiting transplantation. This imbalance in
pulmonary donor organs is the most severe of all transplanted
organs, with the best procurement average by any OPO in the
United States at approximately 30%. Therefore any attempt to
increase the number of donor lungs is a laudable objective.
Straznicka and coworkers report that of the 194 donors from
their OPO who donated lungs, resulting in 224 transplants, 27
donors were deemed unacceptable for lung donation because of
oxygenation values less than the standard threshold PaO2/FIO2 ratio
of 150. They demonstrated that 1-month and 1-year survivals were
not statistically significantly different from results obtained with
initially acceptable lung donors. Paradoxically, in fact, the surviv-
als of patients who received lungs from unacceptable lung donors
were better than those who received lungs from an ideal subset of
the acceptable donors. There is no question that donors with
initially poor oxygenation can be effectively managed to provide
excellent donor lungs. Furthermore, Straznicka and coworkers
provide evidence that these lungs will support recipients for as
long as 1 year after transplantation.
I have a few observations about the study. It is limited by the
small number of patients and its retrospective nature. The statis-
tical comparison of survivals at 1 month and 1 year by the Student
t test is not valid, and an actuarial analysis such as Kaplan-Meier
method with log-rank testing for significance is needed. The com-
parison of results between the groups is problematic, because the
recipient diagnoses were not accounted for in this analysis. It is
possible that the initially unacceptable lungs were transplanted into
the best recipients and that the ideal donor lungs were placed into
recipients at higher risk. We know that this situation partially
exists in this study, because the survival in the ideal group was the
lowest in all the groups and this was the only group that supplied
lungs to heart-lung recipients. Certainly many recipient factors that
affect outcome are independent of the quality of lungs during the
procurement process. The PaO2/FIO2 ratio was the only discrimi-
nator used to include donors in the unacceptable group. The
optimization maneuvers used were generally procedures that are
standard with good donor management, such as diuresis, bronchos-
copy, and monitoring of chest radiographs. The use of steroids is
the only factor that was outside the standard of care, and this is
now part of the routine management of all prospective lung donors
in this OPO. Maybe these groups were really quite similar, and the
initial PaO2/FIO2 ratio is a poor predictor of outcome when it is the
only factor considered. The 1-month and 1-year results were
excellent in the unacceptable cohort, but we have no information
about either short-term or long-term recipient pulmonary function.
Specifically, the incidence of obliterative bronchiolitis is unknown,
and this may prove to be an important factor, especially in the
traumatically injured donor group. Finally, we must remember that
at the time of procurement the donor lungs in the unacceptable
group were not only acceptable but trending toward ideal, with
excellent oxygenation and clear chest radiographs.
Dr Straznicka, I have a few questions. What was the denomi-
nator for the 27 patients in the unacceptable group? Specifically,
how many of the 1000 potential lung donors in your OPO during
the study period had PaO2/FIO2 ratios less than 150 that could not
be optimized?
Dr Straznicka. We do not have those data, but it is something
that we will look into in the future.
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Dr Robbins. I suggest that if we were to analyze the data a bit
more carefully, we could learn a lot of valuable information that
could predict which potential donors could have optimization
performed, which could allow us to further expand the donor pool
for lungs into more marginal donors.
Was the PaO2/FIO2 ratio that you reported an initial value
reported to the OPO, or was it the lowest or some average of the
values?
Dr Straznicka. It was the initial PaO2/FIO2 ratio. The initial
PaO2/FIO2 ratio was the one shortly after brain death declaration,
when the decision was made whether the patient could be a
potential lung donor.
Dr Robbins. Do you have any information about whether in
the acceptable donor groups this PaO2/FIO2 ratio was less than 150
at any time during the hospitalization? Is it possible that some of
the acceptable donors had a PaO2/FIO2 ratio less than 150 before
the OPO ever began management? Do you know whether that is
true, or were they always good gas values?
Dr Straznicka. All the blood gas values in the acceptable
donor group showed a PaO2/FIO2 ratio greater than 150 during the
entire period of management.
Dr Robbins. How many patients in the acceptable group had
one or more unacceptable criteria, such as age older than 55 years,
smoking history, abnormal sputum, or chest trauma? Do you have
any idea about information about the patients in the acceptable
group? Were there some unacceptable things about them?
Dr Straznicka. The acceptable group did in fact have one or
more criteria that were not part of the ideal criteria, and for that
reason they were not among the 38 ideal donors, but I do not have
the exact breakdown of which of those criteria each donor had.
Dr Robbins. What were the causes of death among the recip-
ients? There were only a few deaths, but were any of the deaths
related to the poor quality of donor lungs? Do you have any idea
about that?
Dr Straznicka. We do not have information from the trans-
plantation centers on the cause of death of the recipient and
whether it was related to donor factors.
Dr Robbins. In summary, there is an important message in this
article, and that is do not turn down lungs for transplantation just
because of one blood gas value. Approximately 30% of young
donors nationwide have their hearts refused for transplantation on
the basis of poor function from one echocardiogram. There are
certainly many factors that are released during the process of brain
death that serve as negative inotropic agents and contribute to
neurogenic pulmonary edema, and as we have heard today many of
these organs can be salvaged.
A recent conference sponsored by the American Society of
Transplant Surgeons and organized by Bruce Rosengard of the
University of Pennsylvania and attended by a couple of the coau-
thors of this article explored the various methods that one might
use to increase donor use nationwide. There are several prospec-
tive protocols that are currently being written and will be imple-
mented to try to achieve this goal.
The highest rates of OPO procurement of lungs are found in
areas where there is an active lung transplant program and good
communication between the center and the OPO. It certainly is true
that the OPO personnel need to believe that aggressive manage-
ment of these donor lungs will likely produce lungs that we will be
able to transplant, but they also must have the confidence that the
surgeons will use these lungs and be receptive to this aggressive
management.
Dr Michael Mulligan (Seattle, Wash). Articles in the literature
that look at the use of marginal lung donors include the series from
Australia, the Chicago experience out of Loyola, the University of
Virginia experience from Irving Kron’s group, the article from
Toronto recently discussed at the American Association for Tho-
racic Surgery meeting, and a couple of different reports that have
come out of St Louis. No group used an initial PO2 as a criterion
for defining a marginal donor. Everybody used a final PO2, and
many of those donors who were considered ideal had a suboptimal
PO2 at some point. Given that, unless the donors you defined as
marginal had purulent sputum on bronchoscopy, significant smok-
ing history, or age older than 55 years, all of those donors would
have been considered ideal according to the authors of those other
studies. I therefore do not find it entirely surprising that the results
you presented are good.
It may also be that we need to look at these recipients a bit
further out. As you know with significant acute graft dysfunction,
major histocompatibility complex class II expression is much
elevated and they are not only at risk for early morbidity but they
may be at risk for increased difficulty with obliterative bronchi-
olitis long term.
How many of the donors defined as unacceptable at first were
older than 55 years, had significant smoking, or had purulent
bronchoscopy, because all their final chest radiographs were clear?
Dr Straznicka. We have not looked at the data in terms of
which of the extended criteria you mentioned were present in the
acceptable group of donors. That is something that we will look at
in the future.
Dr Mulligan. I also wish to underscore the point of Dr Robbins
about the importance of recipient diagnosis. Groups that have used
marginal donors, truly marginal donors, for patients with persistent
pulmonary hypertension, cystic fibrosis, or idiopathic pulmonary
fibrosis have gotten into a lot of trouble. Conversely, even lungs
with a final PO2 less than 300 mm Hg, purulent secretions that are
unilateral, or a unilateral dense infiltrate can be used as a double-
lung block for a recipient with chronic obstructive pulmonary
disease with excellent results, specifically 5-year survivals that
appear to be in excess of 60%. Ultimately, we do want to use these
marginal lungs, but we may want to be careful about recipient
selection for them.
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